Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-03-04 Declaration of Voting R…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Transparency notification received from The Capital Group
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Transparency notification received from The Capital Group" and explicitly states that Galapagos NV received a transparency notification regarding a change in shareholding percentage by The Capital Group Companies, Inc., which crossed below the 10% threshold. This type of filing, which reports changes in significant share ownership levels by external entities, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document details the percentage held (9.91%) and the date the threshold was crossed, confirming it is a notification of a change in major shareholding.
2021-03-04 English
Transparency notification received from The Capital Group
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantieverklaring ontvangen van The Capital Group" (Transparency declaration received from The Capital Group) and explicitly states that Galapagos NV received a "kennisgeving van belangrijke deelneming" (notification of a major shareholding) from The Capital Group, detailing that their stake dropped below the 10% threshold. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds, as mandated by Belgian transparency laws mentioned in the text. The document is a notification about a change in ownership, not the full annual report (10-K) or an earnings release (ER).
2021-03-04 English
GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV, dated March 4, 2021, announcing interim results from ongoing safety studies (MANTA and MANTA-RAy) regarding the drug filgotinib. It details specific clinical findings (sperm concentration decrease percentages) and explicitly states that the data 'zullen worden ingediend bij de relevante regelgevende instanties' (will be submitted to the relevant regulatory authorities) and that they plan to submit the full results for publication later. This structure—announcing preliminary clinical trial data and stating intent to file with regulators—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a formal announcement of key periodic results (even if related to ongoing trials rather than quarterly financials), and it is not a full financial report (10-K/IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as it conveys the primary financial/clinical news update for the period. It is not a Report Publication Announcement (RPA) because it contains the results themselves, not just the notice that a report is available. Q1 2021
2021-03-04 English
GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
Regulatory Filings Classification · 95% confidence The document is a press release dated March 4, 2021, announcing interim results from clinical safety studies (MANTA and MANTA-RAy) regarding the drug filgotinib. It details specific clinical endpoints, patient data (e.g., sperm concentration decline), and states that the data 'will be submitted to the relevant regulatory authorities.' This format—a concise announcement of key findings from ongoing research or trials, often including forward-looking statements and contact information, but not the full comprehensive financial report (like a 10-K) or a full transcript—is characteristic of an Earnings Release (ER) or a general press release announcing material non-financial information. Since it is focused on clinical trial results and not quarterly financial performance highlights, it is best classified as a general announcement that falls under the scope of material information dissemination. Given the options, and recognizing this is a primary announcement of material, non-financial operational/clinical data, it most closely aligns with an Earnings Release (ER) if we interpret 'Earnings' broadly as 'Results Announcement,' or potentially Regulatory Filing (RNS) if it were less specific. However, the structure strongly suggests an 'Earnings Release' (ER) which often includes operational highlights alongside financial ones, or in this context, a major operational update that warrants immediate public disclosure. Since it is a direct announcement of study results, ER is the most fitting category for a material results announcement, even if the 'results' are clinical rather than purely financial. It is not a full report (IR/10-K), a presentation (IP), or a management discussion (MDA).
2021-03-04 English
GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
Regulatory Filings Classification · 97% confidence The document is a press release dated March 4, 2021, announcing interim results from clinical safety studies (MANTA and MANTA-RAy) regarding the drug filgotinib. It details specific patient data (sperm concentration decline), states that the data will be submitted to 'relevant regulatory authorities,' and discusses future plans for publication. This format—a formal announcement of clinical trial results and regulatory submission intent, often released outside of standard quarterly/annual reporting cycles—is characteristic of an Earnings Release (ER) if it were focused on financial performance, or more specifically, a general regulatory/corporate update. Since it is a specific announcement about clinical data submission and not a full financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) if interpreted broadly as a key operational update, or potentially a Regulatory Filing (RNS) as a general announcement. Given the focus on clinical trial results and the statement 'Data will be submitted to the relevant regulatory authorities,' this is a material operational update often released via an ER mechanism to inform the market promptly. However, since it is not explicitly financial results (like revenue/EPS), and it is a specific announcement about clinical data submission, it aligns closely with the nature of an Earnings Release (ER) which often includes key operational milestones alongside financial highlights, or a Regulatory Filing (RNS) as a catch-all for material non-standard announcements. Given the structure and the immediate market-moving nature of clinical trial data, ER is a strong candidate, but RNS is the safest fallback for material non-financial announcements. Since it is a formal announcement of study results intended for regulatory submission, and not a transcript or a full report, I will classify it as an Earnings Release (ER) as these often encompass major operational/clinical milestones that impact valuation, or RNS. Given the context of Galapagos being a biotech company, clinical updates are primary drivers. I will lean towards ER as these announcements often precede formal financial reports and serve as the primary market communication for operational progress. If it were purely a submission notice without data, RNS would be better. Since it contains data, ER is appropriate.
2021-03-04 English
Galapagos kondigt primaire eindpunt aan van de lopende MANTA en MANTA-RAy veiligheidsstudies met filgotinib
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV, dated March 4, 2021, announcing interim results from ongoing safety studies (MANTA and MANTA-RAy) regarding the drug filgotinib and its effect on sperm parameters. It details preliminary data (8.3% placebo vs 6.7% filgotinib showing a 50% decrease in sperm concentration after 13 weeks) and states that the data 'zullen worden ingediend bij de relevante regelgevende instanties' (will be submitted to the relevant regulatory authorities). This format—a brief announcement of clinical trial results or key findings, often preceding a formal regulatory submission or publication—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing itself, but rather an announcement of clinical data updates, it aligns best with the 'Earnings Release' category, which often includes key operational or clinical milestones announced outside of standard quarterly reporting cycles, or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on clinical trial results and the statement that data will be submitted to regulators, it functions as a significant operational update, fitting the ER definition (initial announcement of periodical/key results). It is not a Report Publication Announcement (RPA) because it contains the results, not just the announcement of the report's availability. Q1 2021
2021-03-04 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.